- Ultragenyx Pharmaceutical Inc at Cowen Health Care Conference- Orphan CNS Panel Discussion TranscriptMar 07, 2023
- AVROBIO Inc Virtual Gaucher Disease Program Update TranscriptDec 07, 2022
- AVROBIO Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- AVROBIO Inc at Needham Healthcare Conference (Virtual) TranscriptApr 12, 2022
- AVROBIO Inc at Barclays Global Healthcare Conference TranscriptMar 15, 2022
- Ultragenyx Pharmaceutical Inc, Alector Inc, Passage Bio Inc, AVROBIO Inc and Annexon Inc in the Orphan CNS Panel at Cowen Health Care Conference (Virtual) TranscriptMar 08, 2022
- AVROBIO Inc Cystinosis Update Call TranscriptFeb 09, 2022
- AVROBIO Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) TranscriptNov 15, 2021
- AVROBIO Inc at Jefferies Gene Therapy/Editing Summit (Virtual) TranscriptOct 28, 2021
- AVROBIO Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2021
- AVROBIO Inc at JMP Securities Life Sciences Virtual Conference TranscriptJun 17, 2021
- AVROBIO Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 09, 2021
- AVROBIO Inc Presents new Clinical Data from Fabry Disease, Cystinosis and Gaucher disease Type 1 Programs TranscriptFeb 08, 2021
- AVROBIO Inc at ICR Virtual Conference TranscriptJan 14, 2021
- AVROBIO Inc Virtual R&D Day TranscriptNov 17, 2020
- AVROBIO Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa (Virtual) TranscriptOct 13, 2020
- AVROBIO Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2020
- Avrobio Inc at WORLDSymposium 2020 TranscriptFeb 11, 2020
- AVROBIO Inc Announces Positive Data from Clinical Trials of AVR-RD-01- Call TranscriptJul 15, 2019
AVROBIO Inc Announces Positive Data from Clinical Trials of AVR-RD-01- Call Transcript
Good day, ladies and gentlemen, and welcome to the AVROBIO announces positive data from clinical trials of AVR-RD-01 investigational gene therapy in Fabry disease. (Operator Instructions) As a reminder, this conference call may be recorded.
I would now like to introduce your host for today's conference, Mr. Erik Ostrowski, Chief Financial Officer of AVROBIO. Please go ahead.
Thank you. Good morning, everyone, and thank you for joining us on the conference call. Earlier this morning, we issued a press release reporting new data on our lead gene therapy program in Fabry disease. I would refer everyone to the press release and the slides that we will be using on today's call and the link to the live webcast, which are all available on the Investors section of the AVROBIO website at avrobio.com.
Joining me on the call today are Geoff MacKay, AVROBIO's President and CEO; Birgitte Volck, AVROBIO's President of Research and Development; and Chris Mason, our Chief Scientific Officer. Following our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)